Testosterone Cypionate: Initiation, Dosing, and Monitoring
Diagnosis Before Treatment
Testosterone cypionate should only be initiated in men with confirmed testosterone deficiency, defined as total testosterone <300 ng/dL on two separate early morning measurements, combined with consistent symptoms and signs of hypogonadism 1.
Diagnostic Requirements:
- Two separate early morning fasting total testosterone measurements using the same laboratory and assay method 1
- Both values must be <300 ng/dL 1
- Presence of symptoms: reduced libido, erectile dysfunction, decreased energy, reduced muscle mass, depression, poor concentration, or infertility 1
- Physical signs: decreased body hair, gynecomastia, reduced testicular size, or increased body fat 1
Additional Testing Required:
- Measure serum luteinizing hormone (LH) in all patients with low testosterone 1
- Measure serum prolactin if LH is low or low-normal 1
- If prolactin is persistently elevated, evaluate for endocrinologic disorders including pituitary adenoma 1
Dosing Regimen
For hypogonadal men, administer 50-400 mg intramuscular testosterone cypionate every 2-4 weeks, with most men requiring 100-200 mg every 2 weeks 2.
Practical Dosing Approach:
- Start with 100-200 mg every 2 weeks for most adult men 2
- Inject deep into the gluteal muscle 2
- Target mid-normal testosterone range (approximately 400-700 ng/dL) during treatment 3, 4, 5
- Adjust dose based on symptom response and testosterone levels measured at trough (just before next injection) 3
Formulation Considerations:
The ACP recommends intramuscular formulations over transdermal when initiating therapy, as costs are considerably lower and clinical effectiveness and harms are similar 6. However, intramuscular testosterone cypionate causes supraphysiological testosterone peaks that lead to higher estradiol and hematocrit elevations compared to alternative formulations 7, 8.
Absolute Contraindications
Do not initiate testosterone cypionate in men with any of the following 3, 4, 5:
- Breast or prostate cancer
- Palpable prostate nodule or induration
- PSA >4 ng/mL (or >3 ng/mL in high-risk men including African Americans or those with first-degree relatives with prostate cancer) without urological evaluation
- Hematocrit >50%
- Untreated severe obstructive sleep apnea
- Severe lower urinary tract symptoms (International Prostate Symptom Score >19)
- Uncontrolled or severe heart failure (Class III-IV)
- Myocardial infarction or stroke within the last 6 months
- Thrombophilia
- Planning fertility in the near term (testosterone suppresses spermatogenesis) 3
Monitoring Protocol
First Year Monitoring:
Evaluate at 3 months, 6 months, and 12 months after initiation 3:
At each visit, assess:
- Symptom improvement (sexual function, energy, mood)
- Adverse effects
- Treatment compliance
Laboratory monitoring:
- Total testosterone level (trough, just before next injection) - target mid-normal range 3
- Hematocrit - discontinue if >54%, consider dose reduction if 50-54% 3
- PSA - evaluate if increase >1.4 ng/mL within 12 months or >0.4 ng/mL annually thereafter 3
- Estradiol if gynecomastia or mood changes develop 7
After First Year:
- Continue monitoring every 6-12 months indefinitely 3
- Same parameters as first year
Critical Monitoring Caveat:
Intramuscular testosterone cypionate significantly increases hematocrit - in one study, hematocrit rose from 42.7% to 46.6% after just 4 months 8. This is a major safety concern requiring vigilant monitoring. Testosterone cypionate also significantly elevates estradiol levels compared to alternative formulations 7, 8, which may cause gynecomastia and mood disturbances.
Reassessment and Discontinuation
Reevaluate symptoms within 12 months and periodically thereafter 6.
Discontinue testosterone cypionate if:
- No improvement in sexual function after 12 months in men treated primarily for sexual dysfunction 6
- Hematocrit rises above 54% despite dose reduction 3
- Development of contraindications (prostate cancer, cardiovascular events, etc.)
- Patient desires fertility restoration
Important Limitation:
The ACP recommends against initiating testosterone for improving energy, vitality, physical function, or cognition in men with age-related low testosterone, as evidence for these benefits is of low certainty 6. The primary indication with reasonable evidence is sexual dysfunction 6.
Special Populations
In men with unexplained anemia, bone density loss, diabetes, chemotherapy exposure, testicular radiation, HIV/AIDS, chronic narcotic use, infertility, pituitary dysfunction, or chronic corticosteroid use, measure testosterone even without typical symptoms 1, as these conditions increase risk of hypogonadism.